Penny Stocks To Buy Now?
Are you looking for penny stocks to buy now? If your answer is “yes,” you’re not alone. But before you dive headfirst into something someone on Reddit posted, you’ll want to make sure to do a few things first. For starters, find the types of stocks you’re looking to trade.
Whether it’s momentum-based, fundamental-based, technical trading, or a mix of everything, determining the “stuff” you want to trade is key. Your next step is to put together your list of penny stocks to watch. Narrow this down further for when you are ready to pull the trigger and then decide if it’s time to buy or avoid entirely. This article looks at some of the more popular penny stocks to watch this week.
Best Penny Stocks To Buy [or avoid]
- Acorda Therapeutics (NASDAQ: ACOR)
- PAVmed Inc. (NASDAQ: PAVM)
- Atara Biotherapeutics (NASDAQ: ATRA)
- Atossa Therapeutics (NASDAQ: ATOS)
- Xeris Biopharma Holdings (NASDAQ: XERS)
Acorda Therapeutics (NASDAQ: ACOR)
The stock market might be down today, but that doesn’t seem to have hurt the micro-cap arena. Biotech penny stocks are some of the most active in the stock market today. These small companies tend to move unrelated to broader markets because of their speculative nature and potential to make significant jumps on any type of news or corporate event.
[Read More] 3 Hot Penny Stocks To Watch With The Stock Market Down TodayAcorda Therapeutics is one of the recent examples of that, and lat-October has been a very active period for the company. Acorda first caught attention after winning an arbitration award of $16.5 million. A licensing dispute with Alkermes tipped in favor of Acorda about certain licensing royalties from AMPYRA. According to company management, the award gives the company a more competitive rate for supplying the treatment and reducing costs. The arbitration win came after more than two years of work to make it happen. Acorda initially filed the demand for arbitration in July 2020.
Fast-forward about a week, and ACOR stock is waking up again. The move comes just a few days before a virtual Q&A with CEO Ron Cohen, M.D. The call will review items from Acorda’s Special Meeting of Shareholders, which will happen next week on November 4th. In light of this, speculative trading trends seem to have reemerged, and ACOR stock is back on the radar of retail traders.
PAVmed Inc. (NASDAQ: PAVM)
Another one of the biotech penny stocks on this list is PAVmed. The company develops medical devices for diagnostics and digital health applications. Its subsidiary, Lucid Diagnostics (NASDAQ: LUCD), focuses on cancer prevention and markets EsoGuard and EsoCheck, targeting patients at risk of certain esophageal cancers.
The interesting part about PAVM stock is that there haven’t been many recent developments that might prompt market momentum. Some details related to PAVmed’s commercial pipeline may be a point of focus. In particular, its Veris Health Cancer Care platform was discussed in the second quarter business update. The company discussed plans to launch it this year. While no further details have come out, it may be worth noting as momentum has begun building.
Veris is another one of PAVmed’s subsidiaries and focuses on digital health for personalized cancer care. The cancer care platform is expected to launch with its VerisBox, a bundle of Bluetooth-enabled connected health care devices.
Atara Biotherapeutics (NASDAQ: ATRA)
Shares of Atara Biotherapeutics have steadily moved higher this month. The company’s specialty is in T-cell immunotherapeutics. Last month, it received a near-term milestone payment under an existing agreement with Pierre Fabre in commercializing tab-cel for Epstein-Barr virus-positive cancers. Atara announced it would get $30 million upon tab-cel’s EC approval and Marketing Authorization Application filing transfer to Pierre Fabre. Considering the anticipated approval for this is Q4 of 2022, timing has come into focus.
A few weeks ago, the company also announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for EC approval. This approval was for Ebvallo for treating patients with relapsed or refractory Epstein-Barr virus-positive lymphoproliferative disease.
Pascal Touchon, President and CEO of Atara, explained that “if approved, EbvalloTM will be the first ever allogeneic T-cell therapy and has the potential to change the treatment paradigm for patients with relapsed or refractory EBV+ PTLD who face a poor prognosis and dismal median survival of only weeks to a few months.”
With multiple “expected” outcomes as the backdrop, ATRA stock has turned heads in the stock market this week.
Atossa Therapeutics (NASDAQ: ATOS)
News this morning helped give Atossa a boost in the market. The company announced receipt of authorization from the FDA to begin its Phase 2 study of (Z)-endoxifen in premenopausal women with specific receptors related to breast cancer. This marked the first study of Atossa’s (Z)-endoxifen platform in the US.
CEO Steven Quay, M.D., Ph.D., also mentioned that the company had engaged Dr. Matthew Goetz. He is the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. at Mayo Clinic, and Director of the Mayo Clinic Breast Cancer SPORE. Dr. Goetz will serve as the lead principal investigator for this multi-center study.
“We look forward to opening the study in the fourth quarter,” said Dr. Quay.
In light of a pending study opening this quarter and on top of today’s update, ATOS stock could be one of the names to watch.
Xeris Biopharma Holdings (NASDAQ: XERS)
Last week Xeris Biopharma Holdings announced clinical data, and since then, XERS stock has been on the rise. The company reported positive topline Phase 1 results from its investigational subcutaneous XP-8121 platform. Xeris said the data support further development in patients with congenital or acquired hypothyroidism requiring thyroid hormone replacement.
[Read More] Penny Stocks & The Stock Market This Week October 24-28 [Infographic]Interestingly, like several companies on this penny stock list, Xeris is also expecting an event by the end of the year. In this case, it anticipates an FDA end-of-phase 1 interaction before 2023.
CEO Paul R. Edick mentioned, “The Phase 1 study results offer initial proof of concept that our novel subcutaneous formulation of levothyroxine has the potential to provide patients with a once-weekly dosing, thereby potentially improving treatment adherence, as well as bypassing the gastrointestinal (GI) tract, thereby mitigating limitations of oral therapy.”
In light of these latest milestones, XERS stock could be one of the companies to follow. Jefferies recently assumed coverage on the penny stock with a Buy and $4 price target.
If you enjoyed this article and you’re interested in learning how to trade so you can have the best chance to profit consistently then you need to checkout this YouTube channel. CLICK HERE RIGHT NOW!!
